BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31179501)

  • 1. An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice.
    Hamoudi D; Marcadet L; Piette Boulanger A; Yagita H; Bouredji Z; Argaw A; Frenette J
    Hum Mol Genet; 2019 Sep; 28(18):3101-3112. PubMed ID: 31179501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.
    Dufresne SS; Boulanger-Piette A; Bossé S; Argaw A; Hamoudi D; Marcadet L; Gamu D; Fajardo VA; Yagita H; Penninger JM; Russell Tupling A; Frenette J
    Acta Neuropathol Commun; 2018 Apr; 6(1):31. PubMed ID: 29699580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-RANKL Therapy Prevents Glucocorticoid-Induced Bone Loss and Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.
    Jayash SN; Hamoudi D; Stephen LA; Argaw A; Huesa C; Joseph S; Wong SC; Frenette J; Farquharson C
    Calcif Tissue Int; 2023 Oct; 113(4):449-468. PubMed ID: 37470794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice.
    Wada E; Tanihata J; Iwamura A; Takeda S; Hayashi YK; Matsuda R
    Skelet Muscle; 2017 Oct; 7(1):23. PubMed ID: 29078808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.
    Boulanger Piette A; Hamoudi D; Marcadet L; Morin F; Argaw A; Ward L; Frenette J
    Curr Osteoporos Rep; 2018 Oct; 16(5):541-553. PubMed ID: 30225627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANKL Inhibition Reduces Cardiac Hypertrophy in
    Marcadet L; Juracic ES; Khan N; Bouredji Z; Yagita H; Ward LM; Tupling AR; Argaw A; Frenette J
    Cells; 2023 Jun; 12(11):. PubMed ID: 37296659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utrophin haploinsufficiency does not worsen the functional performance, resistance to eccentric contractions and force production of dystrophic mice.
    Boulanger Piette A; Hamoudi D; Marcadet L; Kyomi Labelle F; Ovidiu David R; Bossé S; Argaw A; Frenette J
    PLoS One; 2018; 13(6):e0198408. PubMed ID: 29879154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice.
    Zhou L; Rafael-Fortney JA; Huang P; Zhao XS; Cheng G; Zhou X; Kaminski HJ; Liu L; Ransohoff RM
    J Neurol Sci; 2008 Jan; 264(1-2):106-11. PubMed ID: 17889902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice.
    Messina S; Bitto A; Aguennouz M; Minutoli L; Monici MC; Altavilla D; Squadrito F; Vita G
    Exp Neurol; 2006 Mar; 198(1):234-41. PubMed ID: 16410003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
    Gutpell KM; Hrinivich WT; Hoffman LM
    PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifelong quercetin enrichment and cardioprotection in Mdx/Utrn+/- mice.
    Ballmann C; Denney TS; Beyers RJ; Quindry T; Romero M; Amin R; Selsby JT; Quindry JC
    Am J Physiol Heart Circ Physiol; 2017 Jan; 312(1):H128-H140. PubMed ID: 27836895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deubiquitinating enzyme A20 negatively regulates NF-κB signaling in skeletal muscle in mdx mice.
    Charan RA; Hanson R; Clemens PR
    FASEB J; 2012 Feb; 26(2):587-95. PubMed ID: 22012122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone.
    Messina S; Bitto A; Aguennouz M; Mazzeo A; Migliorato A; Polito F; Irrera N; Altavilla D; Vita GL; Russo M; Naro A; De Pasquale MG; Rizzuto E; Musarò A; Squadrito F; Vita G
    Exp Neurol; 2009 Dec; 220(2):349-58. PubMed ID: 19786019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice.
    Hamoudi D; Bouredji Z; Marcadet L; Yagita H; Landry LB; Argaw A; Frenette J
    Hum Mol Genet; 2020 Feb; 29(3):483-494. PubMed ID: 31943048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease of myofiber branching via muscle-specific expression of the olfactory receptor mOR23 in dystrophic muscle leads to protection against mechanical stress.
    Pichavant C; Burkholder TJ; Pavlath GK
    Skelet Muscle; 2016; 6():2. PubMed ID: 26798450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers.
    Hnia K; Gayraud J; Hugon G; Ramonatxo M; De La Porte S; Matecki S; Mornet D
    Am J Pathol; 2008 Jun; 172(6):1509-19. PubMed ID: 18458097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct roles of TRAF6 at early and late stages of muscle pathology in the mdx model of Duchenne muscular dystrophy.
    Hindi SM; Sato S; Choi Y; Kumar A
    Hum Mol Genet; 2014 Mar; 23(6):1492-505. PubMed ID: 24163132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy.
    Acharyya S; Villalta SA; Bakkar N; Bupha-Intr T; Janssen PM; Carathers M; Li ZW; Beg AA; Ghosh S; Sahenk Z; Weinstein M; Gardner KL; Rafael-Fortney JA; Karin M; Tidball JG; Baldwin AS; Guttridge DC
    J Clin Invest; 2007 Apr; 117(4):889-901. PubMed ID: 17380205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
    Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
    Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.